Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Glaukos Co. stock logo
GKOS
Glaukos
$100.33
+2.8%
$93.13
$77.10
$163.71
$5.73B0.8728,882 shs1.25 million shs
LivaNova PLC stock logo
LIVN
LivaNova
$45.50
-0.6%
$40.81
$32.48
$57.35
$2.48B0.9641,862 shs409,159 shs
Penumbra, Inc. stock logo
PEN
Penumbra
$260.63
+1.6%
$275.79
$148.00
$310.00
$10.09B0.49451,117 shs874,400 shs
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
€24.07
+2.5%
€22.55
€16.56
€25.75
$7.29B0.53341,018 shs695,600 shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Glaukos Co. stock logo
GKOS
Glaukos
+2.70%+6.12%+5.11%-0.03%-10.90%
LivaNova PLC stock logo
LIVN
LivaNova
-0.57%-1.73%+2.48%+12.60%-13.63%
Penumbra, Inc. stock logo
PEN
Penumbra
+1.69%+1.57%-7.28%-5.36%+38.79%
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
+2.86%+3.44%+0.42%+9.81%+35.45%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Glaukos Co. stock logo
GKOS
Glaukos
4.4469 of 5 stars
4.42.00.04.41.72.50.6
LivaNova PLC stock logo
LIVN
LivaNova
3.4821 of 5 stars
3.54.00.00.03.21.71.3
Penumbra, Inc. stock logo
PEN
Penumbra
4.6393 of 5 stars
3.45.00.03.71.42.51.9
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
1.6175 of 5 stars
0.04.01.70.01.30.01.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Glaukos Co. stock logo
GKOS
Glaukos
2.75
Moderate Buy$134.6734.23% Upside
LivaNova PLC stock logo
LIVN
LivaNova
3.00
Buy$59.2930.30% Upside
Penumbra, Inc. stock logo
PEN
Penumbra
2.88
Moderate Buy$302.4016.03% Upside
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
2.86
Moderate BuyN/AN/A

Current Analyst Ratings Breakdown

Latest LIVN, PEN, STVN, and GKOS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/20/2025
LivaNova PLC stock logo
LIVN
LivaNova
Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradePeer Perform ➝ Outperform$60.00
5/13/2025
LivaNova PLC stock logo
LIVN
LivaNova
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$64.00 ➝ $64.00
5/8/2025
LivaNova PLC stock logo
LIVN
LivaNova
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$56.00 ➝ $55.00
5/8/2025
LivaNova PLC stock logo
LIVN
LivaNova
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$55.00 ➝ $61.00
5/6/2025
Glaukos Co. stock logo
GKOS
Glaukos
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$110.00 ➝ $72.00
5/2/2025
Glaukos Co. stock logo
GKOS
Glaukos
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$140.00 ➝ $115.00
5/1/2025
Glaukos Co. stock logo
GKOS
Glaukos
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$140.00 ➝ $135.00
5/1/2025
Glaukos Co. stock logo
GKOS
Glaukos
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$140.00 ➝ $115.00
5/1/2025
Glaukos Co. stock logo
GKOS
Glaukos
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$176.00 ➝ $115.00
5/1/2025
Glaukos Co. stock logo
GKOS
Glaukos
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Equal Weight$160.00 ➝ $86.00
4/24/2025
Penumbra, Inc. stock logo
PEN
Penumbra
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$320.00 ➝ $330.00
(Data available from 6/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Glaukos Co. stock logo
GKOS
Glaukos
$404.52M14.17N/AN/A$9.46 per share10.61
LivaNova PLC stock logo
LIVN
LivaNova
$1.28B1.95$4.08 per share11.15$23.72 per share1.92
Penumbra, Inc. stock logo
PEN
Penumbra
$1.24B8.14$2.48 per share105.01$29.88 per share8.72
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
$1.12B6.48€1.00 per share23.97€4.15 per share5.80
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Glaukos Co. stock logo
GKOS
Glaukos
-$134.66M-$2.37N/AN/AN/A-39.04%-16.53%-10.61%7/30/2025 (Estimated)
LivaNova PLC stock logo
LIVN
LivaNova
$17.55M-$4.09108.3314.49N/A1.91%13.81%7.07%7/30/2025 (Estimated)
Penumbra, Inc. stock logo
PEN
Penumbra
$90.95M$1.06766.5552.022.831.17%9.74%7.35%7/29/2025 (Estimated)
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
$157.62M€0.5151.2141.507.1810.47%9.86%5.79%N/A

Latest LIVN, PEN, STVN, and GKOS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/30/2025Q1 2025
Glaukos Co. stock logo
GKOS
Glaukos
-$0.33-$0.22+$0.11-$0.32$102.78 million$106.66 million
4/23/2025Q1 2025
Penumbra, Inc. stock logo
PEN
Penumbra
$0.66$0.83+$0.17$1.00$315.72 million$324.14 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Glaukos Co. stock logo
GKOS
Glaukos
N/AN/AN/AN/AN/A
LivaNova PLC stock logo
LIVN
LivaNova
N/AN/AN/AN/AN/A
Penumbra, Inc. stock logo
PEN
Penumbra
N/AN/AN/AN/AN/A
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
€0.060.25%N/A11.76%1 Years

Latest LIVN, PEN, STVN, and GKOS Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/2/2025
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
annual€0.060.3%6/5/20256/5/20257/17/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Glaukos Co. stock logo
GKOS
Glaukos
0.19
5.54
4.71
LivaNova PLC stock logo
LIVN
LivaNova
0.46
3.37
2.87
Penumbra, Inc. stock logo
PEN
Penumbra
0.02
6.01
3.25
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
0.22
1.81
1.21

Institutional Ownership

CompanyInstitutional Ownership
Glaukos Co. stock logo
GKOS
Glaukos
99.04%
LivaNova PLC stock logo
LIVN
LivaNova
97.64%
Penumbra, Inc. stock logo
PEN
Penumbra
88.88%
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
N/A

Insider Ownership

CompanyInsider Ownership
Glaukos Co. stock logo
GKOS
Glaukos
5.80%
LivaNova PLC stock logo
LIVN
LivaNova
0.29%
Penumbra, Inc. stock logo
PEN
Penumbra
4.20%
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
0.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Glaukos Co. stock logo
GKOS
Glaukos
78057.14 million51.61 millionOptionable
LivaNova PLC stock logo
LIVN
LivaNova
2,90054.53 million54.15 millionOptionable
Penumbra, Inc. stock logo
PEN
Penumbra
3,90038.73 million36.59 millionOptionable
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
4,650302.84 million300.72 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Glaukos stock logo

Glaukos NYSE:GKOS

$100.33 +2.73 (+2.79%)
Closing price 06/16/2025 03:59 PM Eastern
Extended Trading
$100.06 -0.27 (-0.27%)
As of 06/16/2025 05:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

LivaNova stock logo

LivaNova NASDAQ:LIVN

$45.50 -0.26 (-0.57%)
Closing price 06/16/2025 04:00 PM Eastern
Extended Trading
$44.88 -0.62 (-1.37%)
As of 04:06 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.

Penumbra stock logo

Penumbra NYSE:PEN

$260.63 +4.13 (+1.61%)
Closing price 06/16/2025 03:59 PM Eastern
Extended Trading
$260.98 +0.36 (+0.14%)
As of 06/16/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

Stevanato Group stock logo

Stevanato Group NYSE:STVN

€24.07 +0.59 (+2.51%)
As of 06/16/2025 03:52 PM Eastern

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.